Claims
- 1. A therapeutic composition in a dosage unit form selected from the group consisting of a tablet, a capsule, a suppository, and a cachet effective in inhibiting the release of chemical mediators that are responsible for the symptoms of allergic diseases comprising an amount, effective in inhibiting said release, of a compound of the formula: ##STR37## wherein R.sub.1 is an alkyl group having from one to six carbon atoms;
- R.sub.2 is lower alkyl having from one to three carbon atoms or is hydrogen;
- n.sub.1, n.sub.2 and n.sub.3 represent the number of CH.sub.2, C(R.sub.2).sub.2 and CH.sub.2 groups, respectively, and are numbers within the range from 0 to 10; and at least one of n.sub.1, n.sub.2 and n.sub.3 is other than zero; and
- an insert pharmaceutically acceptable carrier.
- 2. The composition of claim 1 wherein n.sub.2 and n.sub.3 are zero, and n.sub.1 is from 2 to 8.
- 3. The composition of claim 2 wherein R.sub.1 is tert-butyl.
- 4. The composition of claim 1 wherein each of R.sub.2 is methyl, n.sub.1 is 2, n.sub.2 is 1, and n.sub.3 is 0.
- 5. The composition of claim 1 wherein R.sub.1 is selected from n-propyl, i-propyl, sec-butyl and n-pentyl, n.sub.2 and n.sub.3 are 0, n.sub.1 is 2-8.
- 6. A method for inhibiting the release of chemical mediators that are responsible for the symptoms of allergic diseases in animals in need of said treatment, which comprises administering to the animal an amount, effective to inhibit said release, of a compound of the formula: ##STR38## wherein R.sub.1 is an alkyl group having from one to six carbon atoms; and
- R.sub.2 is lower alkyl having from one to three carbon atoms or is hydrogen;
- n.sub.1, n.sub.2 and n.sub.3 represent the number of CH.sub.2, C(R.sub.2).sub.2 and CH.sub.2 groups, respectively, and are numbers within the range from 0 to 10; and at least one of n.sub.1, n.sub.2 and n.sub.3 is other than zero.
- 7. The method of claim 6 wherein n.sub.2 and n.sub.3 are zero, and n.sub.1 is from 2 to 8.
- 8. The method of claim 6 wherein R.sub.1 is tert-butyl.
- 9. The method of claim 6 wherein each of R.sub.2 is methyl, n.sub.1 is 2, n.sub.2 is 1, and n.sub.3 is 0.
- 10. The method of claim 6 wherein R.sub.1 is selected from n-propyl, i-propyl, sec-butyl and n-pentyl, n.sub.2 and n.sub.3 are 0, n.sub.1 is 2-8.
- 11. The method of claim 6 wherein said administering is oral administration.
- 12. The method of claim 6 which comprises administering the compound of formula 1 in dosage unit form.
Parent Case Info
This application is a divisional of U.S. Ser. No. 047,379, filed 7 May 1987, which issued as U.S. Pat. No. 4,816,491, on 28 Mar. 1989, and which is a continuation of U.S. Ser. No. 551,453, filed 27 Dec. 1983, and now abandoned, which is a divisional of U.S. Ser. No. 327,141, filed 3 Dec. 1981, now issued as U.S. Pat. No. 4,451,474, on 29 May 1984, and which is a continuation-in-part of U.S. Ser. No. 114,183, filed 22 Jan. 1980, and now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
2134001 |
Mills et al. |
Oct 1938 |
|
2158959 |
Coleman et al. |
May 1939 |
|
3954965 |
Boghosian et al. |
May 1976 |
|
4816491 |
Berger et al. |
Mar 1989 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
47379 |
May 1987 |
|
Parent |
327141 |
Dec 1981 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
551453 |
Dec 1983 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
114183 |
Jan 1980 |
|